Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors.

Gayed BA, O'Malley KJ, Pilch J, Wang Z.

Clin Transl Sci. 2012 Feb;5(1):39-42. doi: 10.1111/j.1752-8062.2011.00376.x. Epub 2012 Feb 23.

2.

Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.

Pourgholami MH, Cai ZY, Badar S, Wangoo K, Poruchynsky MS, Morris DL.

BMC Cancer. 2010 Apr 15;10:143. doi: 10.1186/1471-2407-10-143.

3.

The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.

Jing C, Ning J, Yuanjie N.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2137-43. doi: 10.1007/s00432-012-1295-y. Epub 2012 Aug 7.

PMID:
22868821
4.

Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.

Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, Chu CY, Chen RJ, Chang KJ, Yang PC, Kuo ML.

J Natl Cancer Inst. 2006 Jul 19;98(14):984-95.

PMID:
16849681
5.
6.

A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.

Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Sonawane V, Rathos MJ, Kumar S, Joshi KS.

BMC Cancer. 2011 Aug 5;11:338. doi: 10.1186/1471-2407-11-338.

7.

Effect of small interference RNA targeting HIF-1alpha mediated by rAAV combined L: -ascorbate on pancreatic tumors in athymic mice.

Chen C, Sun J, Liu G, Chen J.

Pathol Oncol Res. 2009 Mar;15(1):109-14. doi: 10.1007/s12253-008-9063-7. Epub 2008 May 29.

PMID:
18509748
8.

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.

Patten SG, Adamcic U, Lacombe K, Minhas K, Skowronski K, Coomber BL.

BMC Cancer. 2010 Dec 15;10:683. doi: 10.1186/1471-2407-10-683.

9.
10.

Coordinated action of hypoxia-inducible factor-1α and β-catenin in androgen receptor signaling.

Mitani T, Harada N, Nakano Y, Inui H, Yamaji R.

J Biol Chem. 2012 Sep 28;287(40):33594-606. Epub 2012 Aug 3.

11.

Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.

Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ.

Carcinogenesis. 2012 Feb;33(2):404-12. doi: 10.1093/carcin/bgr290. Epub 2011 Dec 8.

12.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

13.

Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.

Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):15-27. doi: 10.1038/pcan.2011.51. Epub 2011 Nov 15.

PMID:
22083267
14.

Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.

Liu XQ, Xiong MH, Shu XT, Tang RZ, Wang J.

Mol Pharm. 2012 Oct 1;9(10):2863-74. Epub 2012 Sep 4.

PMID:
22924580
15.

Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.

Lu N, Hui H, Yang H, Zhao K, Chen Y, You QD, Guo QL.

Eur J Pharm Sci. 2013 May 13;49(2):220-6. doi: 10.1016/j.ejps.2013.02.018. Epub 2013 Mar 15.

PMID:
23501055
16.

(-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α.

He L, Zhang E, Shi J, Li X, Zhou K, Zhang Q, Le AD, Tang X.

Cancer Chemother Pharmacol. 2013 Mar;71(3):713-25. doi: 10.1007/s00280-012-2063-z. Epub 2013 Jan 6.

PMID:
23292117
17.

Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.

Zhang Y, Won SH, Jiang C, Lee HJ, Jeong SJ, Lee EO, Zhang J, Ye M, Kim SH, Lü J.

Pharm Res. 2012 Jun;29(6):1595-608. doi: 10.1007/s11095-012-0670-3. Epub 2012 Jan 27.

PMID:
22281759
18.

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW.

J Natl Cancer Inst. 1996 Jun 19;88(12):794-801.

PMID:
8637045
19.

Rhapontigenin inhibited hypoxia inducible factor 1 alpha accumulation and angiogenesis in hypoxic PC-3 prostate cancer cells.

Jung DB, Lee HJ, Jeong SJ, Lee HJ, Lee EO, Kim YC, Ahn KS, Chen CY, Kim SH.

Biol Pharm Bull. 2011;34(6):850-5.

20.

Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1α.

Nepal M, Choi HJ, Choi BY, Kim SL, Ryu JH, Kim DH, Lee YH, Soh Y.

Eur J Pharmacol. 2012 Sep 15;691(1-3):28-37. doi: 10.1016/j.ejphar.2012.06.028. Epub 2012 Jul 1.

PMID:
22760073

Supplemental Content

Support Center